{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:08:59Z","timestamp":1792382939209,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), enhancing survival and quality of life. However, kidney transplant recipients (KTRs) are at high risk for bone disorders, particularly low bone turnover disease, which increases fracture risk. Teriparatide, an anabolic agent, may provide a beneficial treatment option for these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>This single-center, retrospective observational study involved 18 KTRs with osteoporosis, low bone turnover, and a history of vertebral or non-vertebral fractures. Patients received teriparatide (20\u00a0\u03bcg\/day) for up to 2 years. Areal bone mineral density (aBMD) at the lumbar spine (LS), total hip (TH), femoral neck (FN), and trabecular bone score (TBS) were measured at baseline, 1 year, and 2 years. In addition, bone turnover markers (BTMs), serum calcium, phosphorus, parathyroid hormone (PTH), and kidney function were monitored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant increases in LS aBMD were observed after 1 year (0.941\u2009\u00b1\u20090.152 vs 1.043\u2009\u00b1\u20090.165, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and maintained after 2 years compared to baseline (0.941\u2009\u00b1\u20090.152 vs 1.074\u2009\u00b1\u20090.154, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). TH aBMD significantly increased after 2 years (0.753\u2009\u00b1\u20090.145 vs 0.864\u2009\u00b1\u20090.141, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), while FN and TBS showed non-significant improvement. Teriparatide was well-tolerated, with mild and transient hypercalcemia and hypophosphatemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Teriparatide significantly improved BMD at the LS and TH in KTRs with osteoporosis and low bone turnover, showing a favorable safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11255-025-04383-8","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:58:00Z","timestamp":1738007880000},"page":"1965-1975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience"],"prefix":"10.1007","volume":"57","author":[{"given":"Daniele","family":"Vetrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Aguanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Passaseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barbuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tondolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cianciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"1170","key":"4383_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/postgradmedj-2021-140341","volume":"99","author":"CC Kao","year":"2023","unstructured":"Kao CC, Wu PC, Chuang MT et al (2023) Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease. Postgrad Med J 99(1170):340\u2013349. https:\/\/doi.org\/10.1136\/postgradmedj-2021-140341","journal-title":"Postgrad Med J"},{"issue":"2","key":"4383_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.ajkd.2017.10.007","volume":"71","author":"M Denburg","year":"2018","unstructured":"Denburg M, Nickolas TL (2018) Declining hip fracture rates in dialysis patients: is this winning the war? Am J Kidney Dis 71(2):154\u2013156. https:\/\/doi.org\/10.1053\/j.ajkd.2017.10.007","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"4383_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2215\/CJN.09500916","volume":"11","author":"SM Moe","year":"2016","unstructured":"Moe SM, Nickolas TL (2016) Fractures in patients with CKD: time for action. Clin J Am Soc Nephrol 11(11):1929\u20131931. https:\/\/doi.org\/10.2215\/CJN.09500916","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"4383_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","volume":"11","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Wiebe N, Knoll G et al (2011) Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11(10):2093\u20132109. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03686.x","journal-title":"Am J Transplant"},{"issue":"10","key":"4383_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ajt.2023.07.006","volume":"23","author":"B Shi","year":"2023","unstructured":"Shi B, Ying T, Chadban SJ (2023) Survival after kidney transplantation compared with ongoing dialysis for people over 70 years of age: a matched-pair analysis. Am J Transplant 23(10):1551\u20131560. https:\/\/doi.org\/10.1016\/j.ajt.2023.07.006","journal-title":"Am J Transplant"},{"issue":"1","key":"4383_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2215\/CJN.03410321","volume":"17","author":"P Khairallah","year":"2022","unstructured":"Khairallah P, Nickolas TL (2022) Bone and mineral disease in kidney transplant recipients. Clin J Am Soc Nephrol 17(1):121\u2013130. https:\/\/doi.org\/10.2215\/CJN.03410321","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4383_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5500\/wjt.v5.i4.222","volume":"5","author":"L D'Marco","year":"2015","unstructured":"D\u2019Marco L, Bellasi A, Mazzaferro S, Raggi P (2015) Vascular calcification, bone and mineral metabolism after kidney transplantation. World J Transplant 5(4):222\u2013230. https:\/\/doi.org\/10.5500\/wjt.v5.i4.222","journal-title":"World J Transplant"},{"issue":"5","key":"4383_CR8","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1046\/j.1523-1755.1998.00142.x","volume":"54","author":"P Messa","year":"1998","unstructured":"Messa P, Sindici C, Cannella G et al (1998) Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54(5):1704\u20131713. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00142.x","journal-title":"Kidney Int"},{"issue":"6","key":"4383_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.V1161093","volume":"11","author":"MC Monier-Faugere","year":"2000","unstructured":"Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH (2000) High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11(6):1093\u20131099. https:\/\/doi.org\/10.1681\/ASN.V1161093","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"4383_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1359\/JBMR.040912","volume":"19","author":"A Cohen","year":"2004","unstructured":"Cohen A, Sambrook P, Shane E (2004) Management of bone loss after organ transplantation. J Bone Miner Res 19(12):1919\u20131932. https:\/\/doi.org\/10.1359\/JBMR.040912","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4383_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00198-003-1532-y","volume":"15","author":"LM Vautour","year":"2004","unstructured":"Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT (2004) Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 15(2):160\u2013167. https:\/\/doi.org\/10.1007\/s00198-003-1532-y","journal-title":"Osteoporos Int"},{"issue":"7","key":"4383_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s1047-2797(01)00226-5","volume":"11","author":"KC Abbott","year":"2001","unstructured":"Abbott KC, Oglesby RJ, Hypolite IO et al (2001) Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 11(7):450\u2013457. https:\/\/doi.org\/10.1016\/s1047-2797(01)00226-5","journal-title":"Ann Epidemiol"},{"issue":"23","key":"4383_CR13","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","volume":"288","author":"AM Ball","year":"2002","unstructured":"Ball AM, Gillen DL, Sherrard D et al (2002) Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288(23):3014\u20133018. https:\/\/doi.org\/10.1001\/jama.288.23.3014","journal-title":"JAMA"},{"key":"4383_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115554","volume":"140","author":"K Iseri","year":"2020","unstructured":"Iseri K, Carrero JJ, Evans M et al (2020) Fractures after kidney transplantation: Incidence, predictors, and association with mortality. Bone 140:115554. https:\/\/doi.org\/10.1016\/j.bone.2020.115554","journal-title":"Bone"},{"issue":"6","key":"4383_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients [published correction appears in J Bone Miner Res. 2011 Nov;26(11):2793]. J Bone Miner Res 26(6):1368\u20131376. https:\/\/doi.org\/10.1002\/jbmr.309","journal-title":"J Bone Miner Res"},{"issue":"6","key":"4383_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/ndt\/gfg116","volume":"18","author":"GB Spasovski","year":"2003","unstructured":"Spasovski GB, Bervoets AR, Behets GJ et al (2003) Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 18(6):1159\u20131166. https:\/\/doi.org\/10.1093\/ndt\/gfg116","journal-title":"Nephrol Dial Transplant"},{"key":"4383_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cca.2019.10.035","volume":"501","author":"P Evenepoel","year":"2020","unstructured":"Evenepoel P, Cavalier E, D\u2019Haese PC (2020) Bone biomarkers in de novo renal transplant recipients. Clin Chim Acta 501:179\u2013185. https:\/\/doi.org\/10.1016\/j.cca.2019.10.035","journal-title":"Clin Chim Acta"},{"issue":"6","key":"4383_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.kint.2018.12.024","volume":"95","author":"P Evenepoel","year":"2019","unstructured":"Evenepoel P, Claes K, Meijers B et al (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95(6):1461\u20131470. https:\/\/doi.org\/10.1016\/j.kint.2018.12.024","journal-title":"Kidney Int"},{"issue":"3","key":"4383_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1681\/ASN.2021081081","volume":"33","author":"HS J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen HS, Behets G, Bammens B et al (2022) Natural history of bone disease following kidney transplantation. J Am Soc Nephrol 33(3):638\u2013652. https:\/\/doi.org\/10.1681\/ASN.2021081081","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4383_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2215\/CJN.0000000000000368","volume":"19","author":"HS J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen HS, Claes K, Smout D et al (2024) Associations of changes in bone turnover markers with change in bone mineral density in kidney transplant patients. Clin J Am Soc Nephrol 19(4):483\u2013493. https:\/\/doi.org\/10.2215\/CJN.0000000000000368","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4383_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrneph.2009.192","volume":"6","author":"HH Malluche","year":"2010","unstructured":"Malluche HH, Monier-Faugere MC, Herberth J (2010) Bone disease after renal transplantation. Nat Rev Nephrol 6(1):32\u201340. https:\/\/doi.org\/10.1038\/nrneph.2009.192","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"4383_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5527\/wjn.v1.i5.127","volume":"1","author":"R Zhang","year":"2012","unstructured":"Zhang R, Chouhan KK (2012) Metabolic bone diseases in kidney transplant recipients. World J Nephrol 1(5):127\u2013133. https:\/\/doi.org\/10.5527\/wjn.v1.i5.127","journal-title":"World J Nephrol"},{"issue":"10","key":"4383_CR23","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/gfaa359","volume":"36","author":"R Hiramatsu","year":"2021","unstructured":"Hiramatsu R, Ubara Y, Sawa N, Sakai A (2021) Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant 36(10):1900\u20131907. https:\/\/doi.org\/10.1093\/ndt\/gfaa359","journal-title":"Nephrol Dial Transplant"},{"key":"4383_CR24","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2011) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [published correction appears in Kidney Int Suppl (2011). 2017 Dec;7(3):e1. https:\/\/doi.org\/10.1016\/j.kisu.2017.10.001]. Kidney Int Suppl (2011) 7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","DOI":"10.1016\/j.kisu.2017.10.001"},{"issue":"4","key":"4383_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67(4):559\u2013566. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.023","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4383_CR26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1681\/ASN.2017050584","volume":"29","author":"S Salam","year":"2018","unstructured":"Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R (2018) Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. J Am Soc Nephrol 29(5):1557\u20131565. https:\/\/doi.org\/10.1681\/ASN.2017050584","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4383_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.ajkd.2021.07.027","volume":"79","author":"HS J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen HS, Behets G, Viaene L et al (2022) Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 79(5):667-676.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.07.027","journal-title":"Am J Kidney Dis"},{"key":"4383_CR28","doi-asserted-by":"publisher","unstructured":"Minisola S, Cipriani C, Grotta GD et al (2019) Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis 11:1759720X19877994. https:\/\/doi.org\/10.1177\/1759720X19877994","DOI":"10.1177\/1759720X19877994"},{"issue":"4","key":"4383_CR29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MNH.0000000000000798","volume":"31","author":"D Smout","year":"2022","unstructured":"Smout D, J\u00f8rgensen HS, Cavalier E, Evenepoel P (2022) Clinical utility of bone turnover markers in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 31(4):332\u2013338. https:\/\/doi.org\/10.1097\/MNH.0000000000000798","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4383_CR30","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H (2016) Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging 11:1653\u20131659. https:\/\/doi.org\/10.2147\/CIA.S120175","journal-title":"Clin Interv Aging"},{"issue":"1","key":"4383_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59\u201368. https:\/\/doi.org\/10.1007\/s00198-006-0189-8","journal-title":"Osteoporos Int"},{"issue":"2","key":"4383_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1744-9987.12867","volume":"24","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Nakazawa D, Nishio S et al (2020) Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study [published correction appears in Ther Apher Dial. 2023 Dec;27(6):1129. 10.1111\/1744-9987.14044]. Ther Apher Dial 24(2):146\u2013153. https:\/\/doi.org\/10.1111\/1744-9987.12867","journal-title":"Ther Apher Dial"},{"issue":"4","key":"4383_CR33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J et al (2016) Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27(4):1441\u20131450. https:\/\/doi.org\/10.1007\/s00198-015-3377-6","journal-title":"Osteoporos Int"},{"issue":"9","key":"4383_CR34","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C et al (2008) Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 8(9):1864\u20131870. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02327.x","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"4383_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"issue":"6","key":"4383_CR36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bcp.13766","volume":"85","author":"G Tabacco","year":"2019","unstructured":"Tabacco G, Bilezikian JP (2019) Osteoanabolic and dual action drugs. Br J Clin Pharmacol 85(6):1084\u20131094. https:\/\/doi.org\/10.1111\/bcp.13766","journal-title":"Br J Clin Pharmacol"},{"key":"4383_CR37","doi-asserted-by":"publisher","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","volume":"15","author":"MT Wen","year":"2024","unstructured":"Wen MT, Li JC, Lu BW et al (2024) Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1391356. https:\/\/doi.org\/10.3389\/fphar.2024.1391356","journal-title":"Front Pharmacol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04383-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:14:31Z","timestamp":1749017671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04383-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4383"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04383-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study procedures were in accordance with the Helsinki Declaration. The study protocol and consent form were approved by the Ethics Committee of the IRCCS Policlinico Sant\u2019Orsola Hospital-University of Bologna (study ID: 586\/2023\/Oss\/AOUBo). All patients were informed about the experimental protocol and the objectives of the study before providing informed consent and biological samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}